Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

50.1K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.1K
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

1.2K
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of postoperative synbiotics on bacterial infections after liver transplantation: A randomized double-blind placebo-controlled trial.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2026
Same author

Safety, Tolerability, and Pharmacodynamics of GS-4224 in Healthy Participants and Participants With Chronic Hepatitis B.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Demographic profile of potential target populations in community laboratory and emergency department settings for consideration in expanding hepatitis C screening in Aotearoa New Zealand.

Journal of primary health care·2026
Same author

An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.

Nature medicine·2026
Same author

A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D.

The New England journal of medicine·2025
Same author

Letters on "Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment." Authors' Reply.

Alimentary pharmacology & therapeutics·2025

Related Experiment Video

Updated: Mar 9, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K

Future anti-HBV strategies.

Edward J Gane1

  • 1University of Auckland, Auckland, New Zealand.

Liver International : Official Journal of the International Association for the Study of the Liver
|January 5, 2017
PubMed
Summary
This summary is machine-generated.

Developing a finite treatment course for chronic Hepatitis B virus (HBV) infection is crucial. Achieving a functional cure requires eliminating HBV cccDNA and restoring immune responses, moving beyond current lifelong antiviral therapy.

Keywords:
HBV CurecccDNA silencingcore inhibitorimmunomodulatorsiRNA

More Related Videos

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.1K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.7K

Related Experiment Videos

Last Updated: Mar 9, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.1K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.7K

Area of Science:

  • Hepatology
  • Immunology
  • Virology

Background:

  • Current oral antivirals for Hepatitis B virus (HBV) infection necessitate lifelong therapy, posing risks of breakthrough, toxicity, and high costs.
  • A finite treatment regimen is needed for sustained off-treatment virological and clinical response, aiming for a functional cure.

Purpose of the Study:

  • To explore innovative strategies for achieving a complete Hepatitis B virus (HBV) cure, defined by HBsAg clearance and cccDNA elimination.
  • To review current and future therapeutic approaches for overcoming high viral/antigen burden and inadequate immune responses in chronic HBV infection.

Main Methods:

  • Investigating novel immunomodulatory agents, including therapeutic vaccines and TLR agonists, to restore innate and adaptive immunity.
  • Examining small molecule inhibitors targeting various stages of the HBV lifecycle, such as entry, nucleocapsid formation, and assembly/release.
  • Considering strategies like siRNA and checkpoint inhibitors to silence cccDNA and reverse T-cell exhaustion.

Main Results:

  • HBV polymerase inhibitors are currently the only antivirals in clinical use.
  • Multiple novel therapeutic targets and agents are in clinical development to address different aspects of HBV infection.
  • Combination therapy involving immunomodulatory, antiviral, and cccDNA-silencing strategies is likely necessary for a successful HBV cure.

Conclusions:

  • Achieving a functional cure for chronic HBV requires overcoming viral persistence and immune dysfunction.
  • A combination of innovative therapies is essential to achieve sustained virological control and eliminate cccDNA.
  • Future treatment regimens must balance efficacy, safety, administration route, and cost to impact the global burden of HBV.